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Although mortality risk scores for chronic hemodialysis (HD)
patients should have an important role in clinical decision-
making, those currently available have limited applicability,
robustness, and generalizability. Here we applied a modified
Framingham Heart Study approach to derive 1- and 2-year all-
cause mortality risk scores using a 11,508 European incident
HD patient database (AROii) recruited between 2007 and 2009.
This scoring model was validated externally using similar-sized
Dialysis Outcomes and Practice Patterns Survey (DOPPS) data.
For AROii, the observed 1- and 2-year mortality rates were 13.0
(95% confidence interval (CI; 12.3–13.8)) and 11.2 (10.4–12.1)/
100 patient years, respectively. Increasing age, low body mass
index, history of cardiovascular disease or cancer, and use of a
vascular access catheter during baseline were consistent
predictors of mortality. Among baseline laboratory markers,
hemoglobin, ferritin, C-reactive protein, serum albumin, and
creatinine predicted death within 1 and 2 years. When applied
to the DOPPS population, the predictive risk score models
were highly discriminatory, and generalizability remained high
when restricted by incidence/prevalence and geographic
location (C-statistics 0.68–0.79). This new model offers
improved predictive power over age/comorbidity-based
models and also predicted early mortality (C-statistic 0.71). Our
new model delivers a robust and reproducible mortality risk
score, based on readily available clinical and laboratory data.
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Chronic kidney disease (CKD), which has evolved as a global
health burden,1 affects up to 13% of United States (US)2 and
European3 adults, who suffer a high incidence of comor-
bidities and an increased mortality risk4. Mortality rates in
end-stage renal disease patients on chronic HD, relating
mainly to cardiovascular complications and infections,
remains higher than that of many cancers or heart failure,
at up to 19.2 per 100 person-years versus only 1.2 in the
general European population.5
An improved ability to identify those patients at an
increased risk of death appears desirable for several reasons.
Thus, identification of high-risk patients may help focus
efforts on risk mitigation strategies. In addition, a valid,
general, easy-to-use mortality risk score in HD patients could
also be used in patient discussions or when scheduling
transplants. In health-care economics, such a score may
categorize patients in comorbidity-adjusted registries or
reimbursement systems, and inform planning. Furthermore,
it may also serve as a research tool—homogenizing the case
mix entering clinical trials and targeting specific interven-
tions to particular patient subgroups—thus reducing sample
sizes without compromising statistical power.
Previously developed risk scores lack applicability, robust-
ness, and generalizability. An early study by Wright,6 which
categorized patients as ‘low’, ‘medium’, and ‘high’ risk on the
basis of age and comorbidities, was popularized by Khan7
who examined the predictive power of this stratification
(referred subsequently here as the Wright–Khan mortality
index). A scoring system based on prediction model b-
coefficients advanced methodologies, allowing objective
assessment of contributory factors and their weighted
impact.8 Recent large and complex studies9–15 used internal
validation that contributes little to generalizability. Generali-
zability may be further limited by restricted patient popula-
tions,9,13 geographic locations,9,11,15 small sample sizes,11 or
insufficient variables.9,11–14 The current study therefore
aimed to develop, in a large European cohort of incident
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HD patients, risk scores for 1- and 2-year all-cause mortality
and to validate these scores externally in a similarly sized,
predominantly prevalent HD population.
RESULTS
Study population
Between 1 January 2007 and 31 December 2009, 11,508
patients were recruited into the second Analyzing Data,
Recognizing Excellence and Optimizing Outcomes (ARO)
cohort (AROii; Figure 1). Thirty-seven percent of patients
initiated HD within Fresenius Medical Care (FME) facilities;
nevertheless, the overall median dialysis vintage was only
4 days upon admission. Nonchronic HD patients, those with
no laboratory data, and/or those with a history of
transplantation (alone or combined; N¼ 773) were excluded.
In addition, 1013 patients left the study during baseline,
leaving 9722 patients. During the first and second year of
follow-up, 1060 (10.9%) and 654 (9.4%) deaths were
reported, respectively, giving 1- and 2-year mortality rates
of 13.0 (95% CI 12.3–13.8) and 11.2 (95% CI 10.4–12.1) per
100 person-years, respectively. In the first year, 344 (3.5%)
patients left the study owing to a renal transplant, and 1338
(13.8%) patients were lost to follow-up (LTFU); in the
second year, 288 patients (4.1%) received renal transplants
and 600 (8.6%) patients were LTFU. Patients LTFU did not
differ greatly from those who were not (Supplementary
Table S1 online). Of the 1938 LTFU patients, 527 (27.2%)
patients returned to FME after their follow-up stop date.
Patients lost or not lost to transplantation are shown in
Supplementary Table S2 online.
Table 1 shows baseline characteristics of the study
populations. Although AROii and Dialysis Outcomes Prac-
tice Patterns III (DOPPS III) patients were similar in many
aspects, we noted some differences. The baseline vascular
access differences between AROii and the third Dialysis
Outcomes Practice Patterns (DOPPS) cohort patients may be
explained by the mix of incident and prevalent patients in
DOPPS. Additional differences include geography, dialysis
vintage, smoking habits, diabetes, cancer, and cardiovascular
disease history. Notably, the proportion of patients dying in
each cohort was similar. Within the DOPPS III cohort, mean
dialysis vintage differed by ‘region’ (Europe: 4.1±5.5 years;
Japan: 6.9±7.1 years; North America: 3.4±4.1 years;
Australasia: 4.5±5.0 years).
Predictors of mortality
In our main AROii analysis (based on a first 3-months on
follow-up baseline), increasing age, low body mass index, and
a cardiovascular disease or cancer history were independently
associated with both 1- and 2-year mortality (Table 2).
Former or current smokers were at a greater risk within 2
years but not at 1 year, as were patients with a CKD etiology
of diabetic nephropathy or tubulo-interstitial disease. Of the
dialysis quality parameters, baseline use of, or change to,
vascular access via a catheter was associated with an increased
risk for both time periods, as was lower actual blood flow.
Lower hemoglobin concentrations were associated with an
increased risk for 1- and 2-year mortality; higher levels were
linked with better survival. Baseline inflammation (increased
C-reactive protein concentrations and high ferritin levels)
was highly predictive of mortality at both 1 and 2 years.
Malnutrition and/or inflammation, as evidenced by low
concentrations of serum albumin, was also consistently
predictive. Predialysis serum creatinine represented an
additional risk marker, with lower values associated with
higher risk, probably reflecting decreased muscular mass and
potentially protein wastage in addition to low serum
albumin. Finally, hypercalcemia was associated with a higher
1-year mortality risk.
The results obtained using a 90- to 180-day baseline were
remarkably consistent with 0- to 90-day baseline observa-
tions, or when LTFU patients were coded as deceased
(Supplementary Table S3 online). Of note, the relationship
between predialysis serum creatinine and mortality was
evident in both analyses, suggesting that any residual renal
function at the time of HD initiation in this incident dialysis
population could not fully explain this association when a 0-
to 90-day baseline was applied.
Risk-score derivation and application
When hazard ratios (HRs) were converted to risk-score
points, extreme age had the greatest risk contribution
(Table 2). A cancer history was generally more disadvanta-
geous than a cardiovascular disease history. Among labora-
tory parameters, elevated C-reactive protein concentrations
contributed the greatest risk, followed by low albumin and
creatinine values. Although lower hemoglobin contributed
additive risk, higher hemoglobin values and lower ferritin
concentrations contributed most to lowering the risk score.
The risk percentage attributable to risk-score totals
differed by follow-up length (Figure 2). The contribution of
modifiable risk markers increased as the risk score increased
(Supplementary Figure S1 online), but only marginally
around 50% of the total risk.
First year events 
(N = 9722):
Second year events 
(N = 6980):
• 288 Kidney Tx (4.1%)
• 600 LTFU (8.6%)
• 654 Died (9.4%)
• 344 Kidney Tx (3.5%)
• 1338 LTFU (13.8%)
• 1060 Died (10.9%)
2742
11,508
10,735
9722
Enrolled
patients
Eligible
patients
Patients in 
main analysis
Did not complete
first year of follow-up
Did not complete
baseline period
Non-
chronic
557
Transplant
history
73
Excluded:
No lab data
320
1733
3
4
1013
773
Figure 1 | Derivation of the AROii study population.
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Table 1 | Baseline characteristics of the study populations and subpopulations
Parameters Ma/NMb
AROii (0–3 Mo)c
(N¼ 9722)
AROii (3–6 Mo)d
(N¼ 8783)
DOPPS III (0–3 Mo)e
(N¼ 10,615)
Incident/prevalent on dialysis (%) NM 100/0 100/0 16/84
Dialysis vintage (months) NM 0.5±1.1 3.4±1.1 53.9±67.9
Dialysis vintage (months) (median [IQRf]) NM 0.1 [0.0, 0.5] 3.1 [3.0, 3.5] 27.9 [9.3, 70.9]
1-year all-cause deaths — 1060 (10.9) 910 (10.4) 1048 (9.9)
2-year all-cause deaths — 1714 (17.6) 1465 (16.7) 1736 (16.4)
Geography:
Europe — 9722 (100) 8783 (100) 4994 (47)
Japan — 0 0 2743 (25.8)
North America — 0 0 2190 (20.6)
Australasia — 0 0 688 (6.5)
Age at baseline (years) NM 64.4±14.7 64.3±14.7 63.4±14.3
Genderg NM
Female 3904 (40.2) 3550 (40.4) 4420 (41.6)
Male 5817 (59.8) 5232 (59.6) 6195 (58.4)
Smoking statusg NM
Nonsmoker 3608 (37.1) 3294 (37.5) 5078 (47.8)
Former 1659 (17.1) 1506 (17.1) 2552 (24.0)
Current 736 (7.6) 685 (7.8) 1505 (14.2)
Missing 3719 (38.3) 3298 (37.5) 1480 (13.9)
Body mass index (kg/m2)g M 26.0±7.8 26.0±5.8 25.1±6.1
Missing 683 (7.0) 474 (5.4) 1038 (9.8)
History of diabetes NM 2740 (28.2) 2536 (28.9) 4189 (39.5)
History of cardiovascular disease NM 2480 (25.5) 2430 (27.7) 6995 (65.9)
History of cancer NM 557 (5.7) 504 (5.7) 1347 (12.7)
Chronic kidney disease etiologyg NM
Hypertension/vascular 1548 (15.9) 1415 (16.1) 1764 (16.6)
Glomerulonephritis 895 (9.2) 811 (9.2) 2415 (22.8)
Diabetes 2335 (24.0) 2136 (24.3) 2901 (27.3)
Tubulo-interstitial 1062 (10.9) 949 (10.8) 968 (9.1)
Polycystic kidney disease 534 (5.5) 490 (5.6) 595 (5.6)
Miscellaneous/other 3106 (31.9) 2793 (31.8) 1220 (11.5)
Invalid/Missing 242 (2.5) 189 (2.2) 752 (7.1)
Vascular access in the first 90 daysg M
No change: Fistula or graft 3154 (32.4) 3990 (45.4) 7802 (73.5)
No change: Catheter 2908 (29.9) 2062 (23.5) 1637 (15.4)
Change: Fistula/graft to catheter 211 (2.2) 193 (2.2) 99 (0.9)
Change: Catheter to fistula/graft 922 (9.5) 809 (9.2) 355 (3.3)
Other 0 0 158 (1.5)
Missing 2527 (26.0) 1729 (19.7) 564 (5.3)
Actual blood flow (ml/min)g M 302.7±131.3 327.1±259.7 294.0±90.0
Missing 920 (9.5) 794 (9.0) 925 (8.7)
Dialysis adequacy (equilibrated Kt/V)g M 1.3±0.5 1.4±0.3 1.5±0.3
Missing 718 (7.4) 458 (5.2) 1375 (13.0)
Intradialytic weight change (kg; post-pre)g M  1.7±0.8  1.9±0.8  2.2±2.7
Missing 75 (0.8) 36 (0.4) 301 (2.8)
Hemoglobin (g/l)g M
o100 2796 (28.8) 935 (10.6) 1248 (11.8)
100 to o120 4966 (51.1) 4015 (45.7) 5473 (51.6)
X120 1638 (16.8) 3613 (41.1) 3849 (36.3)
Missing 322 (3.3) 220 (2.5) 45 (0.4)
Ferritin (mg/l)g M
o500 3847 (39.6) 2386 (27.2) 3342 (31.5)
X500 4822 (49.6) 5383 (61.3) 6629 (62.4)
Missing 1053 (10.8) 1014 (11.5) 644 (6.1)
C-reactive protein (mg/l)g M 15.6±25.3 13.3±23.2 13.7±80.6
Missing 2393 (24.6) 2551 (29.0) 4150 (39.1)
Serum albumin (g/l)g M
o35 2518 (25.9) 1554 (17.7) 2516 (23.7)
X35 5948 (61.2) 5964 (67.9) 7713 (72.7)
Missing 1256 (12.9) 1265 (14.4) 386 (3.6)
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Internal discrimination and calibration
The distribution of 1- and 2-year risk-score points for
patients with and without events is shown in Figure 3, with
the intersection point between patients—8 and 9 points,
respectively—defining ‘high-’ and ‘low-’risk patients. On
applying these cutoffs, the risk score was highly sensitive
(2- and 1-year sensitivity 70.7% (95% CI 68.5–72.8%) and
81.5% (95% CI 79.2–83.9%), respectively) but slightly less
specific (2- and 1-year specificity 66.0% (95% CI
65.0–67.0%) and 56.4% (95% CI 55.3–57.4%), respectively;
Table 3). By extending this risk categorization to tertile
of increasing risk, our risk scores effectively separated
patients in real-life clinical terms; the proportion of patients
in AROii who actually died within 1 and 2 years increased
significantly as tertile of risk increased from ‘low’ through
‘medium’ to ‘high’ (all chi-squared for trend P values
o0.001, respectively; Table 4). Calibration curves—which
essentially answer the question ‘do close to x of 100
patients with a risk prediction of x% have the out-
come?’16—demonstrate a strong linear relationship between
predicted and actual 1- and 2-year mortality (Figure 4).
Greater calibration was observed for 2 years (R2¼ 0.98) than
for 1 year (R2¼ 0.94), possibly reflecting fewer events in the
latter; the consistently lower predicted versus observed
mortality in both accords with the lower specificity described
above.
Risk-score validation
The predictive 1- and 2-year risk scores were highly
discriminatory when applied externally to the DOPPS
population (Table 5). Although generalizability remained
high when the DOPPS population was restricted to distinct
geographic locations, small ‘regional’ differences were noted,
with the predictive value being lower in North America and
Table 1 | (Continued)
Parameters Ma/NMb
AROii (0–3 Mo)c
(N¼ 9722)
AROii (3–6 Mo)d
(N¼ 8783)
DOPPS III (0–3 Mo)e
(N¼ 10,615)
Cholesterol (mmol/l)g M
o3.6 1722 (17.7) 1231 (14.0) 2890 (27.2)
3.6 to o6.0 4589 (47.2) 3463 (39.4) 5385 (50.7)
X6.0 532 (5.5) 423 (4.8) 360 (3.4)
Missing 2879 (29.6) 3666 (41.7) 1980 (18.7)
LDL-cholesterol (mmol/l)g M
o2.6 3240 (33.3) 2385 (27.2) 3692 (34.8)
2.6 to o3.3 1281 (13.2) 859 (9.8) 789 (7.4)
3.3 to o4.1 653 (6.7) 467 (5.3) 341 (3.2)
4.1 to o4.9 182 (1.9) 143 (1.6) 82 (0.8)
X4.9 87 (0.9) 42 (0.5) 23 (0.2)
Missing 4279 (44.0) 4887 (55.6) 5688 (53.6)
Creatinine (mmol/l)g M 565.4±187.6 614.1±201.7 777.9±256.4
Missing 926 (9.5) 925 (10.5) 52 (0.5)
Calcium (mmol/l)g M
o2.1 2742 (28.2) 1884 (21.5) 1576 (14.8)
2.1 to o2.6 6368 (65.5) 6388 (72.7) 8552 (80.6)
X2.6 126 (1.3) 133 (1.5) 377 (3.6)
Missing 486 (5.0) 378 (4.3) 110 (1.0)
Phosphate (mmol/l)g M
o0.8 291 (3.0) 271 (3.1) 83 (0.8)
0.8 to o1.5 4583 (47.1) 3958 (45.1) 3390 (31.9)
X1.5 4527 (46.6) 4335 (49.4) 7064 (66.5)
Missing 321 (3.3) 219 (2.5) 78 (0.7)
Parathyroid hormone (ng/l)g M
o 150 2557 (26.3) 2762 (31.4) 3426 (32.3)
150 to o300 2571 (26.4) 2260 (25.7) 2964 (27.9)
300 to o600 1871 (19.2) 1327 (15.1) 2059 (19.4)
X600 731 (7.5) 463 (5.3) 946 (8.9)
Missing 1992 (20.5) 1971 (22.4) 1220 (11.5)
Abbreviations: AROii, second Analyzing Data, Recognizing Excellence and Optimizing Outcomes (ARO) cohort; DOPPS, Dialysis Outcomes and Practice Patterns Survey;
LDL, low-density lipoprotein.
Categorical variables are reported using n (%). Continuous variables are reported using mean±s.d.
aFactors considered modifiable.
bFactors considered non-modifiable.
cAROii derivation data set using a 0- to 90-day baseline.
dAROii derivation data set using a 90- to 180-day baseline.
eDOPPS III validation data set using a 0- to 90-day baseline.
fInter quartile range.
gVariables where missing values were imputed.
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Table 2 | Risk markers for 1- and 2-year all-cause mortality, with associated derived risk score points, in a European incident
hemodialysis cohort
2-year all-cause mortality 1-year all-cause mortality
Parameter (unit) and values HRa (95% CIb) Pointsc HR (95% CI) Points
Age—continuous (years) 1.04 (1.03–1.04) 1.03 (1.03–1.04)
Age—categorical (years)
p39  5  5
40 to 49  2  2
50 to 59 0 0
60 to 69 2 2
70 to 79 4 4
X80 6 6
Smoking status
Nonsmoker 1 0
Former 1.16 (1.03–1.31) 1
Current 1.28 (1.02–1.59) 1
Body mass index (kg/m2)
o18.5 1.66 (1.36–2.03) 3 1.49 (1.15–1.92) 2
18.5 to o25 1 0 1 0
25 to o30 0.88 (0.78–0.99)  1 0.97 (0.84–1.13) 0
X30 0.80 (0.69–0.92)  1 0.84 (0.70–1.01)  1
Cardiovascular disease history
Yes 1.30 (1.17–1.44) 1 1.33 (1.17–1.51) 2
No 1 0 1 0
Cancer history
Yes 1.75 (1.49–2.05) 3 1.93 (1.60–2.32) 4
No 1 0 1 0
Chronic kidney disease etiology
Hypertension/vascular 1.00 (0.79–1.27) 0
Glomerulonephritis 1 0
Diabetes 1.43 (1.14–1.79) 2
Tubulo-interstitial 1.30 (1.03–1.66) 1
Polycystic kidney disease 0.83 (0.58–1.20)  1
Miscellaneous/other 1.12 (0.89–1.39) 1
Vascular access
No change: Fistula/graft 1 0 1 0
No change: Catheter 1.42 (1.25–1.61) 2 1.48 (1.23–1.76) 2
Change: Fistula/graft to catheter 1.32 (1.06–1.63) 2 1.46 (1.13–1.89) 2
Change: Catheter to fistula/graft 1.08 (0.88–1.34) 0 1.12 (0.84–1.50) 1
Actual blood flow (ml/min)
o267.0 1 0 1 0
267.0–o298.7 0.89 (0.77–1.03)  1 0.86 (0.72–1.03)  1
298.7–o332.1 0.88 (0.76–1.02)  1 0.82 (0.69–0.98)  1
X332.1 0.83 (0.71–0.97)  1 0.82 (0.67–1.00)  1
Hemoglobin (g/l)
o100 1.24 (1.11–1.38) 1 1.30 (1.14–1.49) 2
100 to o120 1 0 1 0
X120 0.82 (0.71–0.96)  1 0.86 (0.71–1.06)  1
Ferritin (mg/l)
o500 0.85 (0.76–0.96)  1 0.84 (0.74–0.97)  1
X500 1 0 1 0
C-reactive protein (mg/l)
o2.6 1 0 1 0
2.6-o7.0 1.31 (1.08–1.59) 2 1.25 (0.97–1.61) 1
7.0-o18.2 1.58 (1.31–1.90) 3 1.63 (1.29–2.05) 3
X18.2 2.11 (1.77–2.53) 4 2.21 (1.78–2.75) 5
Serum albumin (g/l)
o35 1.42 (1.27–1.59) 2 1.66 (1.42–1.94) 3
X35 1 0 1 0
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higher in Japan. Risk stratification capacity was also good,
with observed mortality increasing with tertile of increasing
predicted risk (chi-squared for trend P values o0.001;
Table 4).
Additional discrimination over existing scores
When the previously published Wright–Khan6,7 classification
was applied, 3381 (35%), 4248 (44%), and 2093 patients
(21%) were classified as low, medium, and high risk,
respectively. Compared with medium-risk patients, low-risk
patients experienced a lower event rate (HR 0.41; 95% CI
0.36–0.48), whereas high-risk patients experienced a higher
rate (HR 1.80; 95% CI 1.63–2.00). In this dialysis population,
the predictive power of the Wright–Khan classification was
moderate (area under the curve (AUC) 0.66; Table 6). The
addition of ARO score predictors improved the predictive
power (AUC 0.74), with a net 24 and 27% of patients with
and without events, respectively, correctly reclassified.
Dialysis and laboratory parameters appeared to have the
greatest impact.
Applying the Liu comorbidity index,12 5315 (55%), 1860
(19%), and 2547 (26%) patients were classified as low
(0–3 points), medium (4 points), and high (X5 points)
risk, respectively, and this variable was predictive of
mortality (low- vs. medium-risk HR 0.75; 95% CI
0.66–0.85; high vs. medium risk HR 1.55; 95% CI
1.36–1.77). Nevertheless, the addition of the ARO score
variables improved the predictive power (AUC from 0.60 to
0.75), and a net 35 and 31% of patients with and without
events, respectively, were correctly reclassified. Initially, the
addition of age had the greatest effect, with the subsequent
addition of medical and clinical history contributing little
to correct reclassification. When dialysis and laboratory
parameters were added, however, further correct reclassi-
fication was observed. An additional analysis, based on
the Liu comorbidity index excluding CKD etiology (in
their original study,12 the score was more predictive when
this parameter was removed), gave similar findings
(Supplementary Table S4 online).
Risk prediction over shorter time periods
The 2-year score was highly predictive of 1-year death
(c-index range 0.74–0.75), although less so than the 1-year
score. Importantly, in the subset of patients who had not
commenced HD (N¼ 4247), it effectively predicted mortality
in the first 90 days (c-index¼ 0.71).
DISCUSSION
We describe a sensitive and discriminate mortality risk score
developed using a large European cohort of incident HD
patients. The model was robust, with similar performances in
incident dialysis patients at 0–90 or 90–180 days into chronic
treatment. Of note, our population started dialysis in
2007–2009: it reflects the current state of the art in medical
therapy. In contrast, the most recent previous mortality
risk model study included patients initiating dialysis in
2002–2004.14
Our aim was not to develop a risk score dedicated to
incident patients on HD, but a versatile mortality risk
prediction tool generalizable to the widest possible HD
population, including both incident and prevalent dialysis
patients. External validation in DOPPS confirmed this, with a
high degree of discrimination observed when we validated
the score against the incident subset and the predominantly
prevalent component in DOPPS (Table 5). Generalizability
to HD in other geographic areas was also apparent. The
observed C-statistic generated (B0.73), although ‘acceptable’
rather than ‘excellent,’17 was comparable with the previous
internally validated studies of Couchoud (0.70),9 Cohen
(AUC 0.77),11 and van Walraven (0.75),13 as well as in
internal validation of the Framingham Risk Score (0.7918).
The development of a mortality risk score in a large inter-
national database such as AROii, with external validation in
another independent worldwide data set as DOPPS, goes
significantly beyond previous risk prediction tools. Further-
more, we demonstrate that the use of simple clinical, dialysis,
and laboratory routine parameters improved predictive
ability over more parsimonious models based on comor-
bidities alone or age and comorbidities.
Table 2 | (Continued)
2-year all-cause mortality 1-year all-cause mortality
Parameter (unit) and values HRa (95% CIb) Pointsc HR (95% CI) Points
Creatinine (mmol/l)
o431.1 1.46 (1.23–1.72) 2 1.45 (1.19–1.76) 2
431.1–o539.2 1.19 (1.01–1.41) 1 1.13 (0.91–1.40) 1
539.2–o672.9 1.09 (0.92–1.30) 0 1.09 (0.87–1.35) 0
X672.9 1 0 1 0
Calcium (mmol/l)
o2.1 1.11 (0.98–1.27) 1
2.1 to o2.6 1 0
X2.6 1.68 (1.06–2.65) 3
Multivariate analysis. Parameters significant at the 5% level shown.
aHR, hazard ratio.
bCI, confidence interval.
cRisk-score points.
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Five aspects particularly distinguish this from previously
developed risk scores. First, prior attempts were based on
often-small patient populations confined to one geographic
area.8,9,11,12,14,19 Second, in contrast to other studies,9–14 we
focused exclusively on incident HD patients, thus minimizing
survival bias. Third, we studied patients from various
countries, socioeconomic groups, and health-care systems,
and prospectively collected data without exclusions. Other
recent scores have focused on older dialysis patients,9 trans-
plant wait-listed HD patients,13 or particular socioecono-
mic groups.12 Fourth, we demonstrate the improved
discrimination of our risk predictors over older models6,7
comprising age and/or comorbidities alone, and reinforce
the clinical meaningfulness of our score through risk
stratification capacity analyses. Age and comorbidities
should both be integrated in a risk prediction tool as main
drivers for mortality;20 retaining only comorbidities may
limit predictive power.12,21 This is apparent in the current
study, in which the addition of age alone to the Liu
comorbidity index correctly reclassified a net 35 and 11%
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Figure 2 | Convenient risk-point calculator printout, including conversion from risk points to estimated all-cause mortality and
subsequent categorization in low-, intermediate-, and high-risk groups.
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of patients with and without events (Table 6). Laboratory
parameters provided the most discriminatory advantage in
our score, in line with previous observations.22,23 Finally, and
potentially most relevant clinically, we apply our score to a
population selected for HD but who had not yet initiated
HD, and effectively predict early mortality in this group.
From a methodological viewpoint, our approach lies
toward the simplistic end of the analytic spectrum.
Advantageously, the methods are easily replicable and a
simple risk calculator could be implemented easily (e.g., in
smartphone applications). Like others,9,13,14 we used impu-
tation to deal with missing data; our choice of Cox regres-
sion is also customary.12–14 Other approaches range from
simplistic Kaplan–Meier plots6 to complicated fractional
polynomial13 or bootstrapped logistic regression models.9
More complicated models may improve prognostic ability,24
but additional computational complexity may well outweigh
potential benefits.
Generic indices such as Charlson Comorbidity Index
(CCI)25 or the Index of Co-Existent Disease (ICED),21
although applied to dialysis patients, were not designed for
bedside use and required adaptation.26,27 Although such
scoring systems may be useful in administrative and
economical decision-making, they appear to perform less
well for mortality risk prediction in HD populations.20 Our
score, in which B50% of the variables were potentially
modifiable, may also lay the ground for specific intervention
studies. In contrast to others,10 our score includes notably
few comorbidities. Another recent study supplemented data
on four variables (age, dementia, peripheral vascular disease,
albumin) with a ‘surprise’ question (‘Would I be surprised if
this patient died within the next 6 months?’).11 How-
ever, only 6-month mortality and 500 patients derived from
five US dialysis centers were assessed. Performance of
the ‘surprise’ question in other countries, especially on
long-term outcomes, is unknown and so far not externally
validated.
Clinically, a mortality risk score should be based on
routinely measured parameters, which are easy to derive and
calculate. For example, the ICED evaluation can take trained
people up to 1 h to complete.28 It should also be based on
accurate, objectively measured variables. This excludes, for
example, dementia and congestive heart failure (difficult to
define in dialysis patients), or subjective parameters such as
self-rated health.29 This practical aspect must be balanced
against potential uncontrolled confounding. Highly
subjective parameters—such as the ‘surprise’ question,11,30
however complementary—will invariably depend on
physician background/training and patient knowledge.
Although we do not advocate for a binary measure of risk,
we would argue that the observed high sensitivity (the ability
of the score to correctly identify high-risk patients) is
clinically advantageous in the dialysis setting, as the false
positive rate (those considered low-risk based on their score
but who died nonetheless) will be low.
Our approach has limitations. First, our study is based on
data generated from a single commercial dialysis provider,
and therefore it could be considered less generalizable to the
2-Year mortality 1-Year mortality
Event
No event
Event
No event
14
12
12 14 16 18 20 22 24
Pe
rc
en
t
Pe
rc
en
t
10
10
8
8
9
7
5
3
1
8
6
6
6
4
4
4
2
2
Points Points
2
0 0
0
–
10 –8 –6 –4 –2 11 13 15 17 19 21 23 251 3 5 7 9–9 –7 –5 –3 –1
Figure 3 | The distribution of 1- and 2-year risk score points for European incident hemodialysis patients with and without the event of
interest.
Table 3 | Sensitivity and specificity of the mortality risk scores
among European hemodialysis patients when applied to
high- and low-risk groups
Risk Period Risk Died (%) Survived (%) Total
2-year Low 503 (8.7) 5285 (91.3) 5788
High 1211 (30.8) 2723 (69.2) 3934
Total 1714 8008 9722
Sensitivity: 70.7% [95% CI 68.5–72.8%]
Specificity: 66.0% [95% CI 65.0–67.0%]
1-year Low 196 (3.9) 4883 (96.1) 5079
High 864 (18.6) 3779 (81.4) 4643
Total 1060 8662 9722
Sensitivity: 81.5% [95% CI 79.2–83.9%]
Specificity: 56.4% [95% CI 55.3–57.4%]
Abbreviation: CI, confidence interval.
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wider HD population. Our risk score performed favorably
when applied externally to the DOPPS population, however,
suggesting that it can be applied to a large community of
HD patients, although we acknowledge that it may be less
generalizable to peritoneal dialysis patients. Focusing on one
large provider allowed us a clinical database, which indicates
that recorded outcomes will reflect patients’ diagnoses rather
than health-care providers’ claims for reimbursement, as
might be observed in administrative databases.10,12
Second, we only assessed 90-day, 1-year, and 2-year
mortality, whereas 3-14 or 5-year24 mortality may also be
important. However, where reported, a remarkably similar
C-statistic of 0.75 was obtained in longer analyses.14
Third, patients with no laboratory data were excluded,
but the loss of 500 of B11,000 patients in AROii contrasts
favorably with a recent registry analysis14 in whichB5500 of
11,000 patients were excluded owing to missing data.
Fourth, a relevant portion of patients were LTFU,
especially in the first year, partly reflecting our stringent
definition. When we assumed that nonreturning patients had
died, however, this had no major bearing on our findings.
Fifth, comorbidity severity was not considered. However,
this often introduces subjectivity, and including severity
grade did not improve the model in another analysis.26
Table 4 | Risk stratification capacity of the risk score: estimated versus actual all-cause mortality in hemodialysis cohorts for
patients classed as ‘Low’, ‘Medium’, and ‘High’ risk based on their risk score
Dataset Model-based estimated risk of all-cause mortality
Actual all-cause mortality
2-year 1-year
Died (%) Did not die (%) Died (%) Did not die (%)
AROii Lowa 112 (3.9) 2728 (96.16) 69 (2.2) 3077 (97.8)
Mediumb 391 (13.3) 2557 (86.7) 284 (8.6) 3009 (91.4)
Highc 1211 (30.8) 2723 (69.2) 707 (21.5) 2576 (78.5)
DOPPS Lowd 195 (5.8) 3151 (94.2) 69 (2.4) 2804 (97.6)
Mediume 537 (15.2) 2990 (84.8) 322 (8.3) 3571 (91.7)
Highf 1004 (26.8) 2738 (73.2) 657 (17.1) 3192 (82.9)
Abbreviations: AROii, second Analyzing Data, Recognizing Excellence and Optimizing Outcomes (ARO) cohort; DOPPS, Dialysis Outcomes and Practice Patterns Survey.
aLower tertile of risk (o15% for 2 years;o9% for 1 year).
bIntermediary tertile of risk (15% to o29% for 2 years; 9% to o19% for 1 year).
cUpper tertile of risk (X29% for 2 years; X19% for 1 year).
dLower tertile of risk in the DOPPS population (o15% for 2 years;o9% for 1 year).
eIntermediary tertile of risk in the DOPPS population (15% to o29% for 2 years; 9% too19% for 1 year).
fUpper tertile of risk in the DOPPS population (X29% for 2 years; X19% for 1 year).
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Figure 4 | The relationship between predicted and observed 1- and 2-year mortality in a European incident hemodialysis cohort.
Table 5 | External validation for the AROii mortality risk score
at 1 and 2 years in DOPPS, C-statistic
DOPPS population C-statistic by mortality
a
2-year 1-year
Incident on hemodialysis 0.73–0.75 0.75–0.76
Prevalent on hemodialysis 0.72 0.73
All 0.72 0.72–0.73
Europe 0.72 0.73–0.74
North America 0.68–0.69 0.69–0.70
Australia 0.71–0.73 0.72–0.74
Japan 0.77–0.79 0.77–0.79
aRange over 10 iterations.
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Sixth, potential predictors of death particularly in elderly
dialysis patients—such as late referral, dependency for
transfers, severe behavioral disorders, health-related quality
of life, frailty assessment, and unplanned dialysis9,31—could
not be assessed in our analysis of routinely captured data.
Other predictive parameters in dialysis patients32–35 might
conceivably improve our score.
Seventh, the inclusion of patients receiving kidney
transplants during follow-up may have selected a healthy
cohort, as transplant-listed patients tend to be younger and
healthier. By treating these events as censored observations,
however, we were in accordance with the analytical
recommendations of a recent study focusing on the issue of
renal transplantation as a competing event in survival
analysis in nephrology.36 We acknowledge, however, that
our score may be less generalizable to HD populations with
excessively higher transplant rates than ours (B8%).
Finally, although country-specific predictions might
provide further insights, many subgroups would be too
small for meaningful analyses. Of note, our score yielded
slightly lower C-statistics in the US DOPPS patients
compared with patients in Europe and, in particular, with
patients in Japan. This suggests potentially unmeasured
confounding in the US analysis. Within Europe, the almost
Table 6 | Additional 2-year all-cause mortality discriminatory ability, conferred by different risk predictors, in a European
incident hemodialysis cohort
Analysis Original model New model AUC D AUC Abs IDI NRIEvents NRINon-events
Wright–Khan variable analysis
Independent addition of variables
Wright–Khan — 0.661 — —
Wright–Khan þmedical history 0.679 0.018 0.005 0.23  0.07
Wright–Khan þ clinical factors 0.677 0.016 0.007 0.08 0.07
Wright–Khan þ dialysis 0.687 0.026 0.012 0.33  0.08
Wright–Khan þ labs 0.722 0.061 0.041 0.20 0.24
Cumulative addition of variables
Wright–Khan — 0.661 — —
Wright–Khan þmedical history 0.679 0.018 0.005 0.23  0.07
Wright–Khanþmedical history þ clinical 0.687 0.008 0.006 0.08 0.07
Wright–Khanþmedical historyþ clinical þ dialysis 0.701 0.015 0.010 0.27 0.01
Wright–Khanþmedical historyþ clinicalþdialysis þ labs 0.738 0.036 0.034 0.19 0.21
All vs. Wright–Khan alone
Wright–Khan þmedical historyþ clinicalþ
dialysisþ labs
0.738 0.077 0.056 0.24 0.27
Liu variable analysis
Independent addition of variables
Liu — 0.601 — — — —
Liu þ age 0.696 0.094 0.046 0.35 0.11
Liu þmedical history 0.610 0.009 0.005  0.65 0.80
Liu þ clinical factors 0.622 0.021 0.007  0.01 0.15
Liu þ dialysis 0.642 0.041 0.013 0.27 0.02
Liu þ labs 0.699 0.098 0.051 0.20 0.28
Cumulative addition of variables
Liu — 0.601 — — — —
Liu þ age 0.696 0.094 0.046 0.35 0.11
Liuþ age þmedical history 0.700 0.004 0.003  0.62 0.60
Liuþ ageþmedical history þ clinical 0.709 0.009 0.007 0.05 0.16
Liuþ ageþmedical historyþ clinical þ dialysis 0.721 0.012 0.010 0.32  0.04
Liuþ ageþmedical historyþ clinicalþdialysis þ labs 0.750 0.029 0.030 0.17 0.23
All vs. Liu alone
Liu þ ageþmedical historyþ
clinicalþ dialysisþ labs
0.750 0.149 0.096 0.35 0.31
Abbreviations: Abs IDI, Absolute Integrated Discrimination Improvement; AUC, area under the curve; NRI, (category-free) net reclassification improvement.
Wright–Khan: patients classified as low, medium, and high risk according to the score of Wright et al.6 and Khan et al7; Liu: patients classified into tertile of increasing risk
according to the comorbidity index of Liu et al12; Medical history: CKD etiology (Wright–Khan variable analysis only), history of cancer and/or cardiovascular disease; Clinical:
Body mass index, smoking status; Dialysis: Vascular access change, actual blood flow; Labs: serum albumin, C-reactive protein, hemoglobin, ferritin, and creatinine. NRIEvents
and NRINon-events correspond, respectively, to the proportion of events/nonevents reclassified correctly minus the proportion of events/nonevents reclassified incorrectly. For
DAUC, and Abs IDI, a positive number corresponds to more events/nonevents being reclassified correctly.
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identical score performance in the AROii and DOPPS cohort
strongly suggests that the AROii population is representative
for a larger European population.
In conclusion, we describe a novel mortality risk score,
potentially applicable to all incident or prevalent HD
patients, with improved predictive power over age-/comor-
bidity-based models. Such a tool is now available for research
purposes, allowing either correction for imbalanced mortality
risk within groups or the selection of high-risk patients; the
data may also prove to be useful when communicating with
patients, for example, through highly visual heat-maps
(Supplementary Figure S2 online). Although risk scores
may help generate hypothesis, they can only describe
associations and not establish causality.
MATERIALS AND METHODS
Study population
The ARO research initiative37 comprises European FME HD
patients. Anonymized patient-level medical history data, plus longi-
tudinal laboratory and medication data are captured quarterly, as
are ICD-10-coded hospitalizations and deaths. The study is based on
AROii, which includes consecutive incident (o6 months on
dialysis) adult patients without renal transplantation history
collected from 4300 FME facilities in 14 European countries in
2007–2009. Data on chronic dialysis patients (X10 contiguous HD
sessions) with available laboratory data were restricted further to
patients remaining in the study for X3 months (Figure 1). Patient
data were anonymized, and informed consent was obtained from all
patients by FME.37 Local ethics committees’ approvals were collected.
Follow-up
Follow-up commenced on the date of patients’ first FME HD
session; time at risk was accrued from the end of baseline (first 3
months of follow-up) until patients experienced the event of interest
or were censored: undergoing a renal transplant, being LTFU (445
days without continuous FME dialysis treatment; LTFU), or end of
follow-up (30 September 2011).
Statistical analysis
Statistical analyses, reproduced independently by a second biosta-
tistician, were performed using SAS (Windows version 9.2; SAS,
Cary, NC, USA). Baseline demographic, clinical, dialysis, and
laboratory data were categorized into quartiles or biologically
relevant groups (Table 1). Continuous variables were described
using means and standard deviations; categorical data were reported
as counts and frequencies. Rates per 100 person-years with
accompanying 95% CIs were calculated.
Risk-score derivation
Risk scores were derived using a modified Framingham Heart
Study38 approach. The predictive effect of exposures was determined
using baseline Cox regression models. Ten imputed data sets were
created using Monte-Carlo Markov Chain multiple imputation to
deal with missing observations, with all covariates described in
Table 1 fitted initially. Generated coefficients were combined using
Rubin’s rules,39 and variables with at least one significant (5% level)
stratum were retained. Coefficients were converted to ‘points’, with 1
point indicating the risk equivalent of 5 years additional age; a total
score was computed for each patient by summing all points.
Estimated absolute risk was calculated by substituting the points
total for each risk category in the original Cox model. An algorithm
describing risk score point derivation in detail and including 1- and
2-year risk equations is included in the Supplementary material
online.
Internal discrimination and calibration
A number of analyses were performed to quantify the relationship
between risk score predictions and actual mortality. Traditional
measures of discrimination—sensitivity and specificity—were
calculated, with the predicted low-/high-risk cutoff determined
graphically (Figure 3). This discrimination was extended to further
assess the risk stratification capacity: patients were categorized as
‘low’, ‘medium’, or ‘high’ risk on the basis of tertile, and this was
compared with their actual 1- and 2-year death status. Changes in
the proportion of deaths across these strata were assessed using the
chi-squared test for trend. Finally, calibration was assessed
graphically: patients’ predicted survival was binned into 10% risk
groups, and these data were plotted against observed death,
calculated as the proportion of patients in each group who actually
died.
Contribution of modifiable and non-modifiable risk markers
Further analyses were performed to demonstrate potential clinical
utility. By choosing, for illustrative purposes, modifiable and non-
modifiable risk markers, a risk ‘heat-map’ was constructed. Risk
markers were stratified in a nested 22 arrangement, and the
product of the points contributing to strata was calculated. A low-/
medium-/high-risk ‘traffic-light’ color scheme was applied on the
basis of tertiles of all calculated points.
By assigning risk scores to patient-level risk markers, the relative
contribution of potentially modifiable and non-modifiable (Table 1)
risk markers was calculated: if a patient had a score of 15 and 6 of
these points were from modifiable factors, then it was assumed that
40% of their risk was modifiable. By applying these proportions to
the actual risk percentage of death, the relative contribution of
modifiable with increasing risk score was estimated.
Risk-score validation
External validation was performed using the third DOPPS19,40,41
cohort. This was chosen for reasons of contemporaneousness
(DOPPS: 2005–2008; AROii: 2007–2009) and data comparability.
The DOPPS study design dictates randomly selected incident and
prevalent HD patients from randomly selected dialysis units within
each country, with chosen facilities representing the different
facilities and regions within each country. The seven-group ICD-
10-based CKD etiology category defined in AROii was applied in
DOPPS using ICD-9 diagnostic codes. DOPPS data were also
limited to patients with Z3 months’ follow-up. The discriminatory
ability of the predictive risk-score model was assessed using Harrell’s
C-statistic.42 These scores range from 0 to 1, with 1 indicating a
perfect prediction and 0.5 indicating a chance prediction; values of
0.7–0.8 could be considered acceptable and those of 0.8–0.9 could be
considered excellent.17
Sensitivity analyses
Additional analyses were conducted to assess the impact of our
methodological choices. It was possible that a proportion of patients
LTFU were lost because they withdrew from dialysis as their
condition deteriorated, with these patients censored instead of
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counted as having a mortality event. To assess the potential impact
of such a misclassification, we considered all nonreturning LTFU
patients as deceased on their last observation date and repeated the
analysis. In addition, to test whether the first 90 days of HD, which
represents a high-risk period,43 was less predictive of longer-term
mortality, the AROii baseline was reset to 90–180 days and the
predictor analysis was repeated.
Additional discrimination
Analyses were conducted to assess the additional discriminatory
power of our 2-year risk score over existing risk scores. Those
described by Wright–Khan et al.6,7 and Liu et al.12 were chosen to
represent European and North American patients, respectively.
Patients were classified according to each score and grouped into
low, medium, and high risk (implicit in the Wright–Khan paper;
tertile of patients’ points total (including points for CKD etiology)
for the Liu paper). Separately, and starting with a model containing
this variable, we added independently and sequentially the medical
history, clinical, dialysis, and laboratory parameters. At each stage,
we calculated the AUC, the Integrated Discrimination Improvement,
IDI (‘the increment in the predicted probabilities for the subset
experiencing an event and the decrement for the subset not
experiencing an event’), and the category-free NRIevents and NRInon-
events (the ‘net’ proportion of individuals with/without events
reclassified correctly using the new model over the original model’),
as proposed by Pencina et al.,44 and as calculated by Kennedy.45 46
For the Liu analysis, the inclusion of age was also assessed, as this
comorbidity index omits age.
Risk prediction over shorter time periods
The discriminatory ability of the 2-year risk-score model over
shorter time periods was assessed using Harrell’s C-statistic. First,
the 2-year score was applied to 1-year mortality. Subsequently, the
ability to predict early death (in the first 90 days of dialysis) was
assessed using predialysis data for the subpopulation of patients who
initiated HD in FME facilities. Where data for any risk-score
parameter was missing (e.g., 100% for actual blood flow), the
neutral risk-score point was applied—i.e., zero.
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